Long-term Follow-up of Cognitive and Functional Evolutions of Persons With Isolated Cognitive Complaints or Mild Cognitive Deficits
NCT ID: NCT04111211
Last Updated: 2025-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1028 participants
OBSERVATIONAL
2019-12-03
2024-12-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Many features of dementia render it especially challenging. Indeed development of disease occurs insidiously over the course of years or decade. In addition, the causes of dementia and determinants of its severity are likely multi-factorial.
To overcome these challenges and better understand the causes and course of AD and related disorders, long term follow-up studies of persons at high risk of dementia are required including multidimensional and harmonized assessment of risk factors, phenotypes (cognition, neuropsychiatric symptoms, physical health, self rated health) and endophenotypes (blood markers, genetic markers, neuroimaging markers).
This project proposes an extension of the follow-up of Memento participants over 5 to 10 years with of focus on cognitive outcomes and comorbidities.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MEMENTO-VAScular COmponents of Dementia
NCT02264899
The Evaluation and Follow-up of Individuals With Memory Disorder
NCT00001480
Longitudinal Study of Brain Amyloid imaGing in MEMENTO
NCT02164643
Memantine Versus Donepezil in Early Stages of Alzheimer's Disease
NCT00505167
Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases
NCT02288000
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Individuals at high risk of developing Alzheimer's dementia
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Being included in Memento cohort
* Affiliated person or beneficiary of a social security scheme.
* Participants capable of expressing non objection
* Non objection expressed by the tutor for participants under tutorship
* Non objection expressed by the participant assisted by their guardian for participants under guardianship
* Non objection expressed by the trusted person (in accordance with art. L1111-6 of Code de la Santé Publique) for participants without the capacity to express non-objection and who are not under legal protection measure
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Bordeaux
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Geneviève CHENE, Prof
Role: PRINCIPAL_INVESTIGATOR
CIC-1401 EC - ISPED - CHU de Bodeaux
Geneviève CHENE, Prof
Role: STUDY_CHAIR
CIC-1401 EC - ISPED - CHU de Bodeaux
Carole DUFOUIL, Director
Role: STUDY_DIRECTOR
CIC-1401 EC - ISPED - CHU de Bodeaux
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU d'Amiens
Amiens, , France
AP-HP - CHU Avicenne
Bobigny, , France
CHU de Bordeaux - Pellegrin
Bordeaux, , France
CHU de Clermont-Ferrand
Clermont-Ferrand, , France
Hôpitaux Civils de Colmar
Colmar, , France
CHU de Dijon
Dijon, , France
CHU de Grenoble
Grenoble, , France
CHU de Lille
Lille, , France
AP-HM
Marseille, , France
CHU de Montpellier
Montpellier, , France
CHU de Nancy
Nancy, , France
CHU de Nantes
Nantes, , France
CHRU de Nice - Institut Claude Pompidou
Nice, , France
CHU de Nice - Hôpital de Cimiez
Nice, , France
AP-HP - Hôpital BROCA
Paris, , France
Ap-Hp La Pitié-Salpêtrière
Paris, , France
APHP Groupe Hospitalier Saint Louis Lariboisière Fernand Widal
Paris, , France
CHU de Bordeaux
Pessac, , France
CHU de Poitiers
Poitiers, , France
CHU de Rouen
Rouen, , France
CHU de Saint-Etienne
Saint-Etienne, , France
CHU de Strasbourg
Strasbourg, , France
CHU de Toulouse - Hôpital Purpan
Toulouse, , France
CHU de Toulouse
Toulouse, , France
CHU de Tours
Tours, , France
Hospice Civil de Lyon
Villeurbanne, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHUBX 2019/16
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.